BamSEC and AlphaSense Join Forces
Learn More

EOM Pharmaceutical Holdings, Inc.

Formerly NYSE American: IMUC
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.14
from S-1/A 30 pages Immunocellular Therapeutics, Ltd. 2022 Equity Incentive Plan Adopted by the Board of Directors: October 27, 2022 Approved by the Stockholders: November 15, 2022
12/34/56
EX-10.12
from S-1/A 14 pages Immunocellular Therapeutics, Ltd. Independent Director Agreement Dated as of April 29, 2022
12/34/56
EX-10.4
from S-1/A 20 pages 1. About Azidus
12/34/56
EX-10.11
from S-1 14 pages Material contract
12/34/56
EX-10.10
from S-1 11 pages Material contract
12/34/56
EX-10.7
from S-1 31 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[****]” Statement of Work
12/34/56
EX-10.6
from S-1 7 pages Material contract
12/34/56
EX-10.5
from S-1 11 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[****]” Quote 20-1339-02 Squalamine Lactate Route Selection, Development and Demonstration Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[****]”
12/34/56
EX-10.3
from S-1 3 pages Material contract
12/34/56
EX-10.2
from S-1 6 pages Material contract
12/34/56
EX-10.1
from S-1 18 pages Material contract
12/34/56
EX-10.6
from DRS 7 pages Material contract
12/34/56
EX-10.3
from DRS 3 pages Material contract
12/34/56
EX-10.2
from DRS 6 pages Material contract
12/34/56
EX-10.1
from DRS 18 pages Material contract
12/34/56
EX-10.1
from 10-Q ~5 pages January [__], 2018 Re: Change of Control Bonus Letter Agreement Dear [Name]
12/34/56
EX-10.59
from 10-K 2 pages ImmunoCellular Therapeutics, Ltd. Non-Employee Director Compensation Policy Amended by the Board of Directors: August 29, 2017
12/34/56
EX-10.63
from 10-K 12 pages December 13, 2016 Andrew Gengos ImmunoCellular Therapeutics, Ltd. 23622 Calabasas Road Suite 300 Calabasas, Ca 91302 Dear Andrew: This Letter Sets Forth the Substance of the Separation Agreement (The “Agreement”) Between You and ImmunoCellular Therapeutics, Ltd. (The “Company”)
12/34/56
EX-10.1
from 10-Q ~5 pages Amendment to Employment Agreement
12/34/56
EX-10.1
from 10-Q ~5 pages First Amendment to Lease Extending Lease Term
12/34/56